FDAnews Device Daily Bulletin

XOPENEX HFA METERED-DOSE INHALER NOW AVAILABLE

Dec. 13, 2005
A A

Sepracor Inc. (Nasdaq: SEPR) today announced that XOPENEX HFA(TM) (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler (MDI), is now available by prescription in pharmacies nationwide. XOPENEX HFA is a short-acting beta-agonist indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. The XOPENEX HFA MDI is a portable, hand-held device consisting of a pressurized canister containing medication and a mouthpiece through which the medicine is inhaled.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1123667XSL_NEWSML_TO_NEWSML_WEB.xml)